|Dr. Joseph F. Lawler||Founder & Chairman||N/A||N/A||1973|
|Dr. Daniel Schneeberger M.B.A., M.D.||CEO & Director||N/A||N/A||1985|
|Mr. Rex Merchant CFA||Chief Financial Officer||N/A||N/A||1960|
|Dr. Linda Klumpers Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.